Skip to main content
Top

Drugs

Issue 1/2021

Content (14 Articles)

50 Years On Still Relevant

  • Editorial

Graeme Avery

50 Years of Drugs

  • Editorial

Dene C. Peters

TRPV1-Targeted Drugs in Development for Human Pain Conditions

Mircea Iftinca, Manon Defaye, Christophe Altier

Therapeutic Options in Hereditary Optic Neuropathies

Giulia Amore, Martina Romagnoli, Michele Carbonelli, Piero Barboni, Valerio Carelli, Chiara La Morgia

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer

Diego Kauffmann-Guerrero, Kathrin Kahnert, Rudolf M. Huber

Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy

Nicola Specchio, Alessandro Ferretti, Marina Trivisano, Nicola Pietrafusa, Chiara Pepi, Costanza Calabrese, Susanna Livadiotti, Alessandra Simonetti, Paolo Rossi, Paolo Curatolo, Federico Vigevano

Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update

Kirk E. Evoy, Sarvnaz Sadrameli, Jillian Contreras, Jordan R. Covvey, Alyssa M. Peckham, Megan D. Morrison

Enarodustat: First Approval

Anthony Markham

REGN-EB3: First Approval

Anthony Markham

Correction to: Decitabine/Cedazuridine: First Approval

  • Open Access
  • Correction

Sohita Dhillon

Correction to: Selpercatinib: First Approval

  • Open Access
  • Correction

Anthony Markham

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images